Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMR 261

Drug Profile

IMR 261

Alternative Names: 10-nitro-oleic-acid; CXA-10; IMR-261

Latest Information Update: 27 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Complexa
  • Developer Complexa; Enliven Therapeutics
  • Class Antihypertensives; Nitro compounds; Oleic acids; Small molecules; Unsaturated fatty acids; Urologics
  • Mechanism of Action Heat-shock protein stimulants; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Toll-like receptor 4 antagonists; Xanthine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Focal segmental glomerulosclerosis; Pulmonary arterial hypertension
  • Preclinical Beta-thalassaemia; Sickle cell anaemia
  • No development reported Acute kidney injury; Renal failure

Most Recent Events

  • 23 Feb 2023 Imara Inc has been merged with Enliven Therapeutics to form Enliven Therapeutics
  • 09 Jun 2022 Preclinical pharmacodynamics data presented at the 27th Congress of the European Haematology Association (EHA-2022)
  • 14 Dec 2021 Imara plans clinical trial for Beta-thalassaemia and Sickle cell anaemia in 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top